Good morning :)
$
₹
AXONEX+AI+GROUP+LTD

AXONEX+AI+GROUP+LTD

AXNX

US
Asset Logo

AXONEX+AI+GROUP+LTD

AXNX

US
$1.01—% (+1.01)
$
₹
$1.01—% (+1.01)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Mid Cap

With a market cap of $3.6B the stock is ranked 1713

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

5.45
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.1
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-1.31%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Based on 11 analysts reports

Buy
1 analyst
Hold
10 analysts
Sell
0 analyst

Price Upside

—

Earnings Growth

—

Rev. Growth

—

Company Profile

Company Profile

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California. As of November 15, 2024, Axonics, Inc. operates as a subsidiary of Boston Scientific Corporation.
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California. As of November 15, 2024, Axonics, Inc. operates as a subsidiary of Boston Scientific Corporation.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
37.36
37.36
1Y Return
18.86%
18.86%
Buy Reco %
85.71
85.71
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.71
38.71
1Y Return
3.48%
3.48%
Buy Reco %
88.00
88.00
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
51.76
51.76
1Y Return
17.95%
17.95%
Buy Reco %
76.47
76.47
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
22.85
22.85
1Y Return
1.27%
1.27%
Buy Reco %
65.51
65.51
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
30.83
30.83
1Y Return
19.81%
19.81%
Buy Reco %
79.31
79.31
Compare with Peers

Forecast

Forecast

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

Financials

Financials

Income

Balance Sheet

Cash Flow

109.7
6.5
91.4
-19.1
114.5
6.8
116.1
-0
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Revenue
Net Income
Financial YearQ2 2022Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024Q2 2024Q3 2024
Total Revenue68.9870.3885.9170.6522.7093.1109.7391.40114.56116.19
Net Income-21.44-16.250.66-9.24-7.343.926.57-19.116.89-0.02
Net Profit Margin-31.08%-23.09%0.77%-13.08%-32.33%4.21%5.99%-20.90%6.02%-0.01%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
AXONEX+AI+GROUP+LTD -5.45-
Abbott Laboratories37.363.501.89
Danaher Corporation38.712.951.32
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare AXNX with any stock or ETF
Compare AXNX with any stock or ETF
Comparing from
AXNX
ABT
DHR
Loading...

Frequently asked questions

  1. AXONEX+AI+GROUP+LTD (AXNX) share price today is $1.01 as of October 24, 2026 at 1:28 AM IST. The stock touched a day high of $1.13 and a day low of $0.99.

  2. AXONEX+AI+GROUP+LTD stock trades on US under the ticker symbol AXNX.

  3. AXONEX+AI+GROUP+LTD's market capitalization is $3.62B as of October 24, 2026 at 1:28 AM IST.

  4. AXONEX+AI+GROUP+LTD's price-to-earnings (P/E) ratio is N/A as of October 24, 2026.

  5. AXONEX+AI+GROUP+LTD's price-to-book (P/B) ratio is 5.45 as of October 24, 2026.

  6. Yes, You can buy AXONEX+AI+GROUP+LTD shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy AXONEX+AI+GROUP+LTD shares in three steps: 1. Search AXONEX+AI+GROUP+LTD on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since AXONEX+AI+GROUP+LTD trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in AXONEX+AI+GROUP+LTD (AXNX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 9.9009 shares at the current price of $1.01.

Loading...